

**formoterol 12 micrograms metered dose inhaler (Atimos®
Modulite®)** **No. (349/07)**

Trinity-Chiesi Ltd

Product Update

9 February 2007 (*Issued October 2007*)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

formoterol 12 micrograms metered dose inhaler (Atimos® Modulite®) is accepted for use in NHS Scotland for the relief of broncho-obstructive symptoms in patients with chronic obstructive pulmonary disease (COPD).

It should be used in patients for whom formoterol is an appropriate choice of long-acting beta-agonist and for whom a metered dose inhaler is an appropriate delivery device.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 6 September 2007.

**Vice-Chairman,
Scottish Medicines Consortium**